GTC
RCUS icon

Ghost Tree Capital’s Arcus Biosciences RCUS Stock Holding History

Ghost Tree Capital’s Portfolio RCUS Stock Details RCUS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-75,000
Closed -$1.35M – 66
2023
Q3 		$1.35M Hold
75,000
– – 0.44% 54
2023
Q2 		$1.52M Hold
75,000
– – 0.5% 41
2023
Q1 		$1.37M Buy
+75,000
New +$1.43M 0.4% 47

Other funds holding RCUS

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
IFA
Invus Financial Advisors New York $89.2M AUM 10.79% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Ghost Tree Capital's RCUS Position: Q4 2023 in Review

Ghost Tree Capital sold out of Arcus Biosciences (RCUS) in Q4 2023, closing a stake of 75,000 shares — an estimated $1.35M sold.

Ghost Tree Capital first reported a position in RCUS in Q1 2023 and held it in 3 quarters. The position peaked at $1.52M in Q2 2023. 185 funds tracked by Wall St. Rank hold RCUS as of Q4 2023.

  • Ghost Tree Capital reported no remaining Arcus Biosciences position as of Q4 2023 after selling out during the quarter.
  • Ghost Tree Capital sold 75,000 Arcus Biosciences shares in Q4 2023, an estimated $1.35M.
  • Ghost Tree Capital first reported a position in Arcus Biosciences in Q1 2023 and held it in 3 quarters.
  • Ghost Tree Capital's Arcus Biosciences position peaked at $1.52M in Q2 2023.
  • 185 funds tracked by Wall St. Rank held Arcus Biosciences as of Q4 2023.

Based on Ghost Tree Capital's 13F filing for Q4 2023, filed 14 Feb 2024.